Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 07:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Strengthens Leadership Team with Appointment of Diana M. Brainard, M.D., to the Board of Directors

WALTHAM, Mass., March 08, 2022 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
December 14, 2021 08:00 ET | Source: Affinia Therapeutics

Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer

WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
October 06, 2021 07:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Appoints Carole Faig to Board of Directors

WALTHAM, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene...
September 08, 2021 07:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza Group

Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form...
July 20, 2021 07:10 ET | Source: Affinia Therapeutics

Affinia Therapeutics Announces Collaboration with the Institute of Molecular and Clinical Ophthalmology Basel (IOB) To Rationally Design Novel CNS Promoters for Gene Therapy

– Botond Roska, M.D., Ph.D., world-renowned scientist and Director at IOB and scientific co-founder of Affinia Therapeutics, will oversee collaboration – – Collaboration will expand upon company’s...
May 13, 2021 06:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Presents New Data and Updates on AAV Platform at American Society of Gene and Cell Therapy Annual Meeting

WALTHAM, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and...
May 03, 2021 06:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Closes $110 Million Series B Financing

Financing co-led by EcoR1 Capital and Farallon Capital ManagementProceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and...
April 27, 2021 16:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics to Present New Data and Updates on AAV Platform at the American Society of Gene and Cell Therapy Annual Meeting

WALTHAM, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors...
February 17, 2021 06:30 ET | Source: Affinia Therapeutics

Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and Programs to the Clinic

-- Gene editing expert Charles Albright, Ph.D., joins as chief scientific officer -- -- Gene therapy development expert Petra Kaufmann, M.D., joins as chief medical officer – WALTHAM, Mass., Feb. ...
June 08, 2020 07:00 ET | Source: Affinia Therapeutics

Affinia Therapeutics Announces Appointment of Elliott Sigal, M.D., Ph.D. to the Company’s Board of Directors

WALTHAM, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a platform for rationally designed adeno-associated virus (AAV) vectors and gene...